Compare
Anterix Inc. vs IDT Corp vs Crexendo, Inc.
| Latest fiscal year | Anterix Inc. ATEXRevenue covers only part of its income (partial revenue) | IDT Corp IDT | Crexendo, Inc. CXDO |
|---|---|---|---|
| Year ended | 2026-03-31 | 2025-07-31 | 2025-12-31 |
| Revenue | n/a | $1.23B | $68.17M |
| Revenue growth (YoY) | n/a | +2.1% | +12.0% |
| Gross margin | n/a | 36.2% | n/a |
| Operating margin | n/a | 8.2% | 6.9% |
| Net margin | n/a | 6.2% | 7.4% |
| Net income | $90.64M | $76.09M | $5.07M |
| EPS (Diluted) | $4.83 | $3.01 | $0.16 |
| Operating cash flow | $5.51M | $127.06M | $9.30M |
| Free cash flow | $5.48M | $106.29M | $9.28M |
| Cash & equivalents | $98.53M | $226.50M | n/a |
| Total assets | $465.21M | $626.20M | $77.69M |
| Total liabilities | $202.89M | $295.79M | $13.87M |
| Shareholders' equity | $262.32M | $318.96M | $63.82M |
| Return on year-end equity | 34.6% | 23.9% | 7.9% |
| Shares outstanding | 18.91M | n/a | 31.00M |
Revenue, most recent five fiscal years
| Fiscal year | Anterix Inc. | IDT Corp | Crexendo, Inc. |
|---|---|---|---|
| Latest | n/a | $1.23B Ended 2025-07-31 | $68.17M Ended 2025-12-31 |
| 1 year earlier | n/a | $1.21B Ended 2024-07-31 | $60.84M Ended 2024-12-31 |
| 2 years earlier | n/a | $1.24B Ended 2023-07-31 | $53.20M Ended 2023-12-31 |
| 3 years earlier | n/a | $1.36B Ended 2022-07-31 | $37.55M Ended 2022-12-31 |
| 4 years earlier | n/a | $1.45B Ended 2021-07-31 | $28.09M Ended 2021-12-31 |